Abstract: The last 4 decades have seen the pursuit of antithrombotic medicines targeting molecular mechanisms underlying platelet activation and blood coagulation. Coagulation Factor Xa inhibitors represent a major advance in the 21st century for stroke prevention in non-valvular atrial fibrillation, and for the treatment and prevention of deep venous thromboembolism. Recently, coagulation Factor XIa has emerged as a promising target with genetic, epidemiologic and preclinical evidence supporting the potential for highly effective antithrombotic efficacy with minimal effects on hemostasis. The design and synthesis of compounds targeting key blood coagulation enzymes, Factor Xa and Factor XIa will be discussed, highlighted by the discovery of apixaban (Eliquis®) and BMS-962212, a parenteral first in class Factor XIa inhibitor.

Evolution of potent factor Xa and factor XIa inhibitors, leading to the design and synthesis of apixaban (Eliquis®) and BMS-962212

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.